Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola May Need Randomized Trial For AndexXa Approval. The Question Is When

Executive Summary

Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.

Advertisement

Related Content

User Fee Forecast For May: Approvals Could Sprout In Multiple Divisions
Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial
Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch
Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Can Praxbind Push Pradaxa Ahead?
Boehringer Files Pradaxa Antidote, Could Be First Reversible Novel Anticoagulant

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel